Global Bispecific Antibody Therapeutics Market, By Indication (Oncology, Autoimmune Disease, Others), Drugs (Blinatumomab, Catumaxomab, Duligotumab, Others), Route of Administration (Intravenous, Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In 2018, approximately 4,285,033 new cancer cases were detected in China, according to Globocan's estimations. As a result, the increased global prevalence of cancer necessitates new therapeutic choices, driving up demand for bispecific antibodies. Bispecific antibodies (BsAbs) are antibodies that can bind two distinct antigens simultaneously (or different epitopes of the same antigen). BsAbs have mostly been used to reroute cytotoxic immune effector cells for improved tumor cell killing via antibody-dependent cell-mediated cytotoxicity (ADCC) and other cytotoxic processes mediated by effector cells.
Data Bridge Market Research analyses that the bispecific antibody therapeutics market was valued at USD 523.98 million in 2021 and is expected to reach USD 900.29 million by 2029, registering a CAGR of 7.0% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Oncology, Autoimmune Disease, Others), Drugs (Blinatumomab, Catumaxomab, Duligotumab, Others), Route of Administration (Intravenous, Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Innovent Biologics, Inc. (China), Adimab (U.S.), Affimed GmbH (Germany), Xencor (U.S.), Pieris Pharmaceuticals, Inc. (U.S.), Mereo BioPharma Group plc (U.K.), Sobi (Sweden), TG Therapeutics, Inc (U.S.), Merus (Netherlands), MacroGenics, Inc (U.S.), Genmab A/S (Denmark), Emergent BioSolutions Inc (U.S.), Alteogen (South Korea), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Allergan (Ireland), F. Hoffmann-La Roche Ltd. (Switzerland), Sanofi (France), AstraZeneca (U.K.), Eli Lilly and Company (U.S.), Astellas Pharma Inc. (Japan)
|
|
Market Opportunities
|
|
Market Definition
In a single molecule, bispecific antibodies have two antigen-binding sites. Bispecific antibodies appear in a variety of sizes and shapes, ranging from tiny proteins with two associated antigen-binding fragments to massive IgG-like molecules with additional domains. The therapeutic success of currently existing bispecific antibodies has accelerated bispecific antibody development in oncology. According to Globaldata's database, 106 bispecific antibody compounds are in development. 45 of the 106 bispecific antibody medicines in clinical development are aimed mostly at blood cancers, while the rest are aimed at solid tumors, mostly lung and gastrointestinal cancers.
Bispecific Antibody Therapeutics Market Dynamics
Drivers
- High prevalence rate of cancer
The rise in prevalence rate of cancer across the globe will act as a major driver that will result in the expansion of the market's growth rate. According to the World Health Organization (WHO), cancer, after cardiovascular disorders, is the world's second greatest cause of death, according to the World Health Organization (WHO). It is, nonetheless, one of the most preventable chronic non-communicable diseases. Reduced tobacco use, healthier diets and physical exercise, reduced alcohol usage, and other measures can save approximately 40% of all cancer deaths. Sedentary lifestyle adoption is on the rise, indicating that a huge number of people are active, putting them at a higher risk of contracting cancer. Furthermore, a sedentary lifestyle that includes the consumption of fast food and packaged materials increases the risk of cancer. As a result, an increase in sedentary lifestyle adoption reflects an increase in cancer incidences, necessitating the development of improved cancer therapies.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of the bispecific antibody therapeutics market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, a surging number of government initiatives to spread awareness and increasing the geriatric population will result in the expansion of the bispecific antibody therapeutics market. Along with this, changing lifestyle of people and growing government favorable initiatives will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the bispecific antibody therapeutics market growth.
- Rising number of strategic collaborations
Key players in the global bispecific antibodies market are also looking to buy companies that provide specialized products and projects with the potential to produce significant income. Manufacturers in the market attempt to have a stronger product portfolio than their competitors by acquiring these companies. Amgen Inc. announced the acquisition of Five Prime Therapeutics in March 2021. Amgen's premier cancer portfolio now includes Five Prime's breakthrough pipeline. These factors will boost new market opportunities during the forecast period of 2022-2029.
Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the bispecific antibody therapeutics market growth.
Restraints/Challenges
On the other hand, the high cost associated with the drug development will obstruct the growth rate of bispecific antibody therapeutics market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and strict regulatory scenario will challenge the bispecific antibody therapeutics market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This bispecific antibody therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bispecific antibody therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The bispecific antibody therapeutics market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Recent Development
- In February 2021, Pfizer announced the initiation of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in multiple myeloma. The trial examines the efficacy and safety of elranatamab, a subcutaneous injection, in patients with multiple myeloma who have failed to respond to at least one drug from each of the three primary classes of medicines licensed for the condition. The US Food and Drug Administration has likewise given Elranatamab Fast Track Designation (FDA). Fast Track is a method for accelerating the development and review of novel medications and vaccines that are intended to treat or prevent serious diseases and have the potential to fill an unmet medical need.
Global Bispecific Antibody Therapeutics Market Scope
The bispecific antibody therapeutics market is segmented on the basis of indication, drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Oncology
- Autoimmune Disease
- Others
Drugs
- Blinatumomab
- Catumaxomab
- Duligotumab
- Others
Route of Administration
- Intravenous
- Subcutaneous
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Pipeline Analysis
The bispecific antibody pipeline is quite crowded, with multiple potential medications such as MGD011, AMG330, Solitomab, FS118, GEM33, and others. Janssen's Teclistamab is the most advanced bispecific antibody currently in development for the treatment of relapsed or refractory multiple myeloma. The company submitted a marketing authorization application to the US FDA and the European Medicines Agency in 2022, and it is expected to be approved by the end of the year. The worldwide bispecific antibody market will be driven by new product launches in the coming years.
Bispecific Antibody Therapeutics Market Regional Analysis/Insights
The bispecific antibody therapeutics market is analysed and market size insights and trends are provided by country, indication, drugs, route of administration, end-users and distribution channel as referenced above.
The countries covered in the bispecific antibody therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the bispecific antibody therapeutics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing demand for specific treatment and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the presence of major key players and rise in adoption of newer technologies will further propel the market's growth rate in this region.
Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to growing cases of cancer in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Bispecific Antibody Therapeutics Market Share Analysis
The bispecific antibody therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bispecific antibody therapeutics market.
Some of the major players operating in the bispecific antibody therapeutics market are:
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Sanofi (France)
- AstraZeneca (U.K.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Eli Lilly and Company (U.S.)
- Allergan (Ireland)
- Innovent Biologics, Inc. (China)
- Adimab (U.S.)
- Affimed GmbH (Germany)
- Xencor (U.S.)
- Pieris Pharmaceuticals, Inc. (U.S.)
- Mereo BioPharma Group plc (U.K.)
- Sobi (Sweden)
- TG Therapeutics, Inc (U.S.)
- Merus (Netherlands)
- MacroGenics, Inc (U.S.)
- Genmab A/S (Denmark)
- Emergent BioSolutions Inc (U.S.)
- Alteogen (South Korea)
- Astellas Pharma Inc. (Japan)
SKU-